PREVYMIS (letermovir) injection
PREVYMIS is a CMV DNA terminase complex inhibitor indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
Home | (letermovir) injection
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient inquires under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
PREVYMIS (letermovir) injection
In the US as well as in the EU, letermovir is used for the prevention of cytomegalovirus infection and disease in adult CMV-seropositive recipients of an allogeneic stem cell transplant.
PREVYMIS is a prescription medicine to help to prevent cytomegalovirus (CMV) infection and disease in adults who have received an allogeneic hematopoietic stem cell (bone marrow) transplant. It is not known if PREVYMIS is safe and effective in children under 18 years of age.
In the US as well as in the EU, letermovir is used for the prevention of cytomegalovirus infection and disease in adult CMV-seropositive recipients of an allogeneic stem cell transplant. The therapy is started shortly after the transplantation and typically lasts for 100 days. Although letermovir is a relatively new antiviral, CMV resistance has been documented in stem cell transplantation recipients; although rare, breakthrough infections of prophylactic treatment with letermovir underscores the ongoing selective pressure on CMV’s viral evolution and its continued ability to evade therapeutic suppression through mutations in critical gene regions such as within the UL56 amplicon.
Drug (Brand / Generic): ACOVA / Argatroban
Current Indication: treat or prevent blood clots in adults
Approval Date: Aug 1, 2017
Available as (Form & Strength):
Tablet: 240 mg; 480 mg. (3)
Injection: 240 mg/12 mL (20 mg/mL) or 480 mg/24 mL (20 mg/mL) in a single-dose vial
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ PREVYMIS (letermovir) injection ”. Confirmation of the order for PREVYMIS (letermovir) injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – PREVYMIS
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha